Page last updated: 2024-09-05

sorafenib and lenvatinib

sorafenib has been researched along with lenvatinib in 151 studies

Compound Research Comparison

Studies (sorafenib)	Trials (sorafenib)	Recent Studies (post-2010) (sorafenib)	Studies (lenvatinib)	Trials (lenvatinib)	Recent Studies (post-2010) (lenvatinib)
6,520	730	5,251	975	112	946

Protein Interaction Comparison

Protein	Taxonomy	lenvatinib (IC50)
Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)	0.0162
Platelet-derived growth factor receptor beta	Homo sapiens (human)	0.039
Platelet-derived growth factor receptor alpha	Homo sapiens (human)	0.051
Vascular endothelial growth factor receptor 1	Homo sapiens (human)	0.022
Kinesin-1 heavy chain	Homo sapiens (human)	0.01
Vascular endothelial growth factor receptor 3	Homo sapiens (human)	0.0052
Vascular endothelial growth factor receptor 2	Homo sapiens (human)	0.0035
Nuclear receptor coactivator 4	Homo sapiens (human)	0.01
Coiled-coil domain-containing protein 6	Homo sapiens (human)	0.01

Research

Studies (151)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	65 (43.05)	24.3611
2020's	86 (56.95)	2.80

Authors

Authors	Studies
Jeong, KW; Kim, MS; Kim, Y; Lee, GS; Lee, K; Lee, Y; Song, JY	1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ	1
Funahashi, Y; Ikemori-Kawada, M; Inoue, A; Jestel, A; Matsui, J; Matsushima, T; Okamoto, K; Tsuruoka, A; von König, K	1
Song, M	1
Chen, Y; Jiao, Y; Lu, T; Wang, L; Zhang, D; Zhang, Y	1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP	1
Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES	1
Atkins, J; Busaidy, N; Fu, S; Hong, D; Kurzrock, R; Naing, A; Sherman, S; Wheler, J	1
Ito, K; Sugino, K; Takami, H	1
Colao, A; Faggiano, A; Marotta, V; Sciammarella, C; Vitale, M	1
Karedan, T; Perez, CA; Wang, E	1
Agulnik, M; Carneiro, BA; Carneiro, RM; Giles, FJ; Kopp, PA	1
Kiyota, N	1
Covell, LL; Ganti, AK	1
Cai, J; Ye, X; Zhu, Y	1
de la Fouchardière, C	2
Ellis, LM; Harris, AL; Jayson, GC; Kerbel, R	1
Okano, S	1
Jarzab, B; Krajewska, J; Kukulska, A	1
Calvo, E; Escudier, B; Grünwald, V; Heng, DY; Schmidinger, M	1
Brzostek, T; Kawalec, P; Kózka, M; Malinowska-Lipień, I	1
Camille, N; Dang, RP; Genden, EM; Le, VH; McFarland, D; Miles, BA; Misiukiewicz, KJ; Teng, MS	1
Brose, MS; DeSanctis, Y; Fellous, M; Lin, CC; Pitoia, F; Schlumberger, M; Smit, J; Sugitani, I; Tori, M	1
Cao, V; Chen, L; Huang, W; Ting, J; Wilson, L	1
Agarwal, N; Gill, DM; Vaishampayan, U	1
Gandhi, S; George, S; Jain, RK	1
Pacini, F	1
Agate, L; Bottici, V; Cappagli, V; Danesi, R; Del Re, M; Elisei, R; Giani, C; Lorusso, L; Matrone, A; Molinaro, E; Pieruzzi, L; Puleo, L; Valerio, L; Viola, D	1
Arvat, E; Berardelli, R; Felicetti, F; Gallo, M; Marchisio, F; Nervo, A; Piovesan, A	1
García-Alemán, J; Mancha-Doblas, I; Molina-Vega, M; Sebastián-Ochoa, A; Tinahones-Madueño, F; Trigo-Pérez, JM	1
Baron, A; Blanc, JF; Cheng, AL; Dutcus, C; Evans, TRJ; Finn, RS; Guo, M; Han, G; Han, KH; Ikeda, K; Jassem, J; Komov, D; Kraljevic, S; Kudo, M; Lopez, C; Park, JW; Piscaglia, F; Qin, S; Ren, M; Saito, K; Tamai, T; Vogel, A	1
Thomas, H	1
Burnett, H; Cheng, W; Copher, R; Guyot, P; Li, X; Makin, C; Tremblay, G	1
Chayahara, N; Goto, H; Hirokawa, M; Imamura, Y; Ito, Y; Kasahara, T; Kiyota, N; Minami, H; Miya, A; Miyauchi, A; Mukohara, T; Nagatani, Y; Nibu, KI; Otsuki, N; Suto, H; Toyoda, M	1
Peck-Radosavljevic, M; Pinter, M	1
Finn, RS; Llovet, JM; Montal, R; Sia, D	1
He, XX; Li, QT; Qiu, MJ; Shi, LL; Wang, MM; Xiong, ZF; Yang, SL	1
Andrikou, K; Cascinu, S; Gelsomino, F; Orsi, G; Riggi, L; Rimini, M; Spallanzani, A	1
Ikeda, M; Kaneko, S; Kobayashi, M; Tahara, M	1
Funahashi, Y; Hori, Y; Ichikawa, K; Ito, J; Kato, Y; Kimura, T; Kodama, K; Matsui, J; Nomoto, K; Ozawa, Y; Tabata, K; Takase, K; Yamada, K	1
Cury-Martins, J; Domingues, RB; Macarenco, R; Sanches, JA; Sato-Sano, M; Vasconcelos, R	1
Abelleira, E; Bueno, F; Jerkovich, F; Pitoia, F; Schmidt, A	1
Luo, Y; Peng, C; Wang, G; Wang, J; Wang, Y; Xu, Z; Zhu, W	1
Azuma, M; Copher, R; Ikeda, S; Ishii, M; Izumi, N; Kaneko, S; Kobayashi, M; Kudo, M; Meier, G; Pan, J	1
García Falcone, MG; Jerkovich, F; Pitoia, F	1
Adejoro, O; Chatterjee, D; Copher, R; Dacosta Byfield, SA; Joshi, PR; Worden, FP	1
Gyawali, B; Kesselheim, AS	1
Arai, S; Fukuda, K; Hirata, E; Matsui, J; Nishiyama, A; Ohtsubo, K; Onoda, N; Taira, S; Takeuchi, S; Taniguchi, H; Tanimoto, A; Wang, R; Yamada, T; Yamashita, K; Yano, S	1
Al-Salama, ZT; Scott, LJ; Syed, YY	1
Bouattour, M; Hulin, A; Stocco, J	1
Brown, SR; Buckley, HL; Du, Y; Farnell, K; Flanagan, L; Flux, G; Gonzalez de Castro, D; Gregory, R; Hall, A; Moss, L; Newbold, K; Wadsley, J	1
Alghuzlan, A; Bardet, S; Borget, I; Borson Chazot, F; de la Fouchardiere, C; Do Cao, C; Godbert, Y; Leboulleux, S; Leenhardt, L; Zerdoud, S	1
Cheng, AL; Dutcus, CE; Evans, TRJ; Finn, RS; Han, KH; Ikeda, M; Kraljevic, S; Kudo, M; Piscaglia, F; Ren, M; Sung, MW	1
Li, Z; Zhu, JY	1
Ameigeiras, B; Anders, M; Bermúdez, C; Colombato, L; D'Amico, C; Fernández, N; Gadano, A; Gaite, L; Marciano, S; Piñero, F; Reggiardo, V; Ridruejo, E; Romero, G; Silva, J; Silva, M; Zerega, A	1
Cheng, SQ; Davidson, JC; Lau, WY; Lu, J; Madoff, DC; Qi, X; Teng, GJ; Zhang, XP; Zhong, BY	1
Budolfsen, C; Bæk Møller, N; E Magnusson, N; Grimm, D; Infanger, M; Krüger, M; Wehland, M	1
Chung, JH; Kim, BH; Kim, EY; Kim, M; Kim, TH; Kim, WB; Kim, WG; Lim, DJ; Oh, HS; Park, SY; Shin, DY; Shong, YK	1
Chin, DW; Law, CT; Lee, D; Ng, IO; Shen, J; Tsang, FH; Wei, L; Wong, CC; Wong, CL; Wong, CM; Zhang, A; Zhang, MS	1
Iwasaki, H; Masudo, K; Nakayama, H; Sakai, R; Suganuma, N; Takasaki, H; Toda, S; Yamazaki, H	1
Argentiero, A; Brunetti, O; Delcuratolo, S; Gnoni, A; Licchetta, A; Longo, V; Memeo, R; Solimando, AG	1
Argentiero, A; Brunetti, O; Calabrese, A; Casadei-Gardini, A; Delcuratolo, S; Gnoni, A; Licchetta, A; Longo, V; Silvestris, N; Solimando, AG	1
Li, Q; Li, Y; Liang, R; Lin, Y; Liu, Z; Luo, M; Ye, J; Zhang, J; Zhang, Y	1
Aikata, H; Haruna, K; Ikeda, K; Ikeda, M; Inaba, Y; Izumi, N; Kawaguchi, Y; Kitamura, C; Kobayashi, M; Kudo, M; Kumada, H; Kuromatsu, R; Numata, K; Okita, K; Okusaka, T; Saito, K; Tamai, T; Tateishi, R; Wada, Y; Yamashita, T	1
Bangaru, S; Marrero, JA; Singal, AG	1
Beale, S; Boland, A; Chaplin, M; Duarte, R; Dundar, Y; Fleeman, N; Greenhalgh, J; Houten, R; Shenoy, A	1
Bagust, A; Beale, S; Boland, A; Duarte, R; Dundar, Y; Fleeman, N; Greenhalgh, J; Hounsome, J; Houten, R; Richardson, M; Shenoy, A	1
Faivre, S; Finn, RS; Rimassa, L	1
Crucitta, S; Danesi, R; Del Re, M; Fogli, S; Gianfilippo, G; Porta, C; Rini, BI; Schmidinger, M	1
Fu, JX; Wang, MQ; Wang, XQ; Wang, Y; Yan, JY; Yuan, B; Zhang, JL	1
Kim, JJ; McFarlane, T; Tully, S; Wong, WWL	1
Fujishiro, M; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Ito, T; Kuzuya, T	1
Briggs, A; Daniele, B; Dick, K; Evans, TRJ; Galle, PR; Hubner, RA; Lopez, C; Siebert, U; Tremblay, G	1
Cadenas, M; Chapresto-Garzón, R; Gómez-Bravo, MA; Muntané, J; Navarro-Villarán, E; Negrete, M; Padillo, FJ; Rodríguez-Hernández, MA; Victor, VM	1
Fujisawa, M; Kanda, T; Kuroda, K; Masuzaki, R; Matsumoto, N; Matsuoka, S; Moriyama, M; Ogawa, M; Sasaki, R	1
Hinrichs, JB; Kirstein, MM; Manns, MP; Marwede, T; Pinter, M; Scheiner, B; Semmler, G; Vogel, A; Voigtländer, T; Wacker, F; Wolf, C	1
Kawagishi, N; Kimura, M; Kitagataya, T; Maehara, O; Mizokami, M; Morikawa, K; Nakai, M; Nakamura, A; Natsuizaka, M; Ogawa, K; Ohara, M; Ohnishi, S; Sakamoto, N; Shigesawa, T; Shimazaki, T; Sho, T; Suda, G; Sugiyama, M; Suzuki, K; Takeda, H; Umemura, M; Yamada, R; Yamamoto, K	1
Aikata, H; Ando, Y; Chayama, K; Fujii, Y; Hiramatsu, A; Imamura, M; Kawaoka, T; Kosaka, Y; Morio, K; Murakami, E; Nakahara, T; Suehiro, Y; Takahashi, S; Tsuge, M; Uchikawa, S; Yamaoka, K	1
Chino, T; Ito, KI; Ito, T; Kanai, T; Maeno, K; Oba, T; Ono, M; Shimizu, T; Soma, A	1
Basha, R; Ghabach, B; Narra, K; Neerukonda, L; Sankpal, UT; Sharma, I; Sridhar, S	1
Aikata, H; Aisaka, Y; Ando, Y; Azakami, T; Chayama, K; Fujino, H; Fukuhara, T; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kawaoka, T; Kodama, K; Kosaka, Y; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Naeshiro, N; Nakahara, T; Nonaka, M; Suehiro, Y; Takahashi, S; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S; Yamaoka, K; Yamauchi, M	1
Card, PB; Knox, JJ; Lim, H; Liu, D; Meyers, BM; Ramjeesingh, R; Tam, VC	1
Bruix, J; da Fonseca, LG; Reig, M	1
Bria, E; Cintoni, M; Gasbarrini, A; Mele, MC; Pompili, M; Ponziani, FR; Pozzo, C; Raoul, P; Rinninella, E; Strippoli, A; Tortora, G	2
Costante, G	1
Byrnes, J; Downes, M; Saiyed, M; Scuffham, P; Srivastava, T	1
Jeng, WJ; Lin, CY; Lin, PT; Lin, SM; Sheen, IS; Teng, W	1
Abdouni, A; Allende, DS; Apte, SS; Arechederra, M; Audebert, S; Bazai, SK; Daian, F; Dono, R; Gregoire, D; Hibner, U; Lozano, A; Maina, F; Mead, TJ; Richelme, S; Sequera, C	1
Ahn, SH; Kim, BK; Kim, DY; Kim, KH; Kim, S; Kim, SU; Park, JY	1
Abe, Y; Eguchi, H; Hayashi, Y; Hikita, H; Kodama, T; Maesaka, K; Mita, E; Motooka, D; Myojin, Y; Ohkawa, K; Sakamori, R; Sato, Y; Taguchi, A; Takehara, T; Tanaka, S; Tatsumi, T	1
Bonney, G; Chow, P; Dan, YY; Huang, DQ; Jumat, H; Kow, A; Lee, GH; Lim, SG; Lim, YT; Muthiah, MD; Pang, YH; Shridhar, I; Soon, G; Tan, WX; Wee, A; Zhou, L	1
Kelly, D; O'Kane, GM; Perera, S	1
Aoki, K; Ikeda, A; Kawamura, M; Kokuryu, H; Yamaguchi, D	1
Atsukawa, M; Bang, Y; Casadei-Gardini, A; Cascinu, S; Cucchetti, A; Frassineti, LG; Fukunishi, S; Hiraoka, A; Itobayashi, E; Kim, HD; Koga, H; Kumada, T; Lonardi, S; Masi, G; Nicola, S; Piscaglia, F; Rimassa, L; Rimini, M; Scartozzi, M; Shimose, S; Soldà, C; Tada, T; Torimura, T; Toyoda, H; Tsuj, K; Vivaldi, C; Yoo, C	1
Amthauer, H; Binse, I; Brink, I; Buck, A; Darr, A; Dierks, C; Koch, C; König, U; Kreissl, MC; Luster, M; Reuter, C; Scheidhauer, K; Schott, M; Verburg, FA; Willenberg, HS; Zielke, A	1
Ao, J; Arai, M; Chiba, T; Iwama, A; Kanayama, K; Kanda, T; Kanogawa, N; Kanzaki, H; Kato, J; Kato, N; Kiyono, S; Kobayashi, K; Kondo, T; Koroki, K; Kusakabe, Y; Maeda, T; Maruta, S; Maruyama, H; Mimura, N; Muroyama, R; Nakagawa, R; Nakamoto, S; Nakamura, M; Ogasawara, S; Ohtsuka, M; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yasui, S; Zen, Y	1
Aikata, H; Amioka, K; Ando, Y; Chayama, K; Fujino, H; Fukuhara, T; Hiramatsu, A; Honda, Y; Imamura, M; Kawaoka, T; Kikukawa, C; Kohno, H; Kosaka, Y; Kouno, H; Masaki, K; Mori, N; Morio, K; Murakami, E; Nakahara, T; Naruto, K; Ogawa, Y; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S; Yamauchi, M; Yoshikawa, Y	1
Beenet, L	1
Gonda, K; Inose, T; Ishida, T; Kamei, T; Kato, C; Kitamura, N; Miyagi, S; Nishimura, R; Ohta, M; Tada, H; Takano-Kasuya, M; Une, N; Unno, M	1
Chen, M; Cheng, AL; Dutcus, C; Finn, R; Han, KH; Hayato, S; Ikeda, K; Kobayashi, M; Kudo, M; Kumada, H; Mody, K; Okusaka, T; Piscaglia, F; Qin, S; Ren, M; Ren, Z; Sung, M; Tamai, T; Wyrwicz, L; Yoon, JH	1
Aikata, H; Aisaka, Y; Amioka, K; Ando, Y; Azakami, T; Chayama, K; Chihiro, K; Fujino, H; Fukuhara, T; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kawaoka, T; Kodama, K; Kohno, H; Kosaka, Y; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Naeshiro, N; Nakahara, T; Naruto, K; Nonaka, M; Ogawa, Y; Suehiro, Y; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S; Yamauchi, M; Yoshikawa, Y	1
Hu, Y; Wu, L; Ye, Z; Zhang, X; Zheng, L	1
Bennett, L; Breder, V; Fartoux, L; Hudgens, S; Kudo, M; López, C; Meier, G; Mody, K; Ohtsuka, T; Qin, S; Simon, K; Su, Y; Sung, M; Tamai, T; Vogel, A; Yamashita, T; Yoon, JH	1
Gao, J; Jing, Z; Li, J; Liu, F; Nan, P; Niu, F; Sun, Y; Tian, L; Xie, X; Zhao, X; Zhao, Y; Zhou, L; Zhu, Y	1
Chen, J; Ding, X; Guo, X; Li, W; Liu, X; Shen, Y; Sun, W; Teng, Y; Zheng, L	1
Campani, C; Casadei-Gardini, A; Catalano, M; Marra, F; Mini, E; Roviello, G; Vannini, G	1
Fujishiro, M; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Ito, T; Kuzuya, T; Muto, H	1
Iwamoto, H; Kajiwara, A; Kamachi, N; Kawaguchi, T; Koga, H; Kuromatsu, R; Nakano, M; Niizeki, T; Noda, Y; Okamura, S; Shimose, S; Shirono, T; Tanaka, M; Torimura, T	1
Fujihara, S; Fujita, K; Goda, Y; Iwama, H; Kobara, H; Masaki, T; Morishita, A; Nakahara, M; Nishiyama, N; Shi, T; Takuma, K; Tani, J; Yamada, M; Yoneyama, H	1
Fujii, Y; Goto, M; Hasebe, T; Horioka, K; Isozaki, S; Kamikokura, Y; Konishi, H; Nakajima, S; Nishikawa, Y; Ogawa, K; Sawada, K; Tanaka, H	1
Cho, EJ; Choi, NR; Jang, H; Kim, MA; Kim, YJ; Lee, JH; Lee, YB; Moon, H; Nam, JY; Park, MK; Yoon, JH; Yu, SJ	1
Chang, HJ; Chang, HS; Fang, S; Kim, M; Kim, SY; Kim, Y; Park, KC; Yun, HJ	1
Altayar, O; Estfan, B; Falck-Ytter, Y; O'Shea, R; Shah, R; Su, GL; Sultan, S; Wenzell, C	1
Altayar, O; Chang, CY; Falck-Ytter, Y; Muir, AJ; Shah, R	1
Asahina, Y; Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Okamoto, R; Osawa, L; Sekiguchi, S; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Yamashita, K; Yasui, Y	1
Cho, EJ; Cho, H; Choi, NR; Hong, JH; Hur, MH; Kim, J; Kim, JY; Kim, YJ; Lee, JH; Lee, YB; Park, MK; Yoon, JH; Yu, SJ	1
Cui, M; Wang, L; Xiao, B; Zhang, B	1
Fukushima, M; Haraguchi, M; Honda, T; Miuma, S; Miyaaki, H; Nakao, K; Sasaki, R	1
An, J; Han, S; Kim, HI; Shim, JH	1
Alevizaki, M; Babajanyan, S; Bowles, DW; Brose, MS; Guan, R; Huang, SM; Lamartina, L; Lin, CC; Ozgurdal, K; Peeters, RP; Pitoia, F; Rumyantsev, P; Shen, DH; Smit, JWA; Sugitani, I; Takahashi, S; Tori, M; Tsai, HJ; Worden, F	1
Airoldi, C; Cortellini, A; D'Alessio, A; Demirtas, CO; Fulgenzi, CAM; Gennari, A; Pinato, DJ; Scotti, L	1
Cao, G; Chen, X; Dong, H; Fan, J; Han, X; Ji, H; Jiang, D; Li, Z; Liu, D; Liu, W; Qian, Y; Tan, X; Wei, Z; Xian, L; Yin, J; Yu, H; Zhao, J; Zhao, P; Zhou, X; Zhu, X	1
Cui, Y; Dong, Z; Guo, C; Li, Y; Ma, Y	1
Hou, Y; Hu, W; Tan, K; Wang, Y; Yang, G	1
Castelo, B; Zafón, C	1
Herranz, UA	1
Aldrighetti, L; Arai, T; Atsukawa, M; Burgio, V; Cabibbo, G; Casadei-Gardini, A; Cascinu, S; Cheon, J; Chon, HJ; Claudia, F; D'Alessio, A; De Cobelli, F; Di Costanzo, GG; Foschi, FG; Fukunishi, S; Hatanaka, T; Hiasa, Y; Hiraoka, A; Hirooka, M; Iavarone, M; Iijima, H; Imai, M; Ishikawa, T; Itobayashi, E; Itokawa, N; Iwamoto, H; Joko, K; Kakizaki, S; Kang, B; Kariyama, K; Kawata, K; Koizumi, Y; Kudo, M; Kumada, T; Lonardi, S; Marra, F; Masi, G; Morishita, A; Nagano, T; Naganuma, A; Nakamura, S; Niizeki, T; Nishida, N; Nishimur, T; Nouso, K; Ochi, H; Ogawa, C; Ohama, H; Okubo, T; Pedica, F; Pinato, DJ; Piscaglia, F; Pressiani, T; Ratti, F; Rimassa, L; Rimini, M; Ryoo, BY; Sakamoto, N; Scartozzi, M; Shigeo, S; Shimada, N; Sho, T; Silletta, M; Soldà, C; Suda, G; Tada, T; Tajiri, K; Takaguchi, K; Tamburini, E; Tanaka, T; Tani, J; Toyoda, H; Tsuji, K; Tsutsui, A; Ueshima, K; Yasuda, S; Yoo, C	1
Aratake, Y; Azuma, Y; Harada, S; Higuchi, N; Kohjima, M; Koyanagi, T; Kuniyoshi, M; Kurashige, T; Motomura, K; Mutsuki, T; Nakamura, T; Nakamuta, M; Ohno, A; Ooe, M; Ooho, A; Satoh, T; Senju, T; Sugimoto, R; Tada, S; Tanaka, M; Tanaka, Y; Uchimura, K; Ueda, A; Yamashita, N; Yamashita, S; Yoshimoto, T	1
Chiang, IT; Hsu, FT; Liu, YC; Tsai, JJ; Weng, YS	1
Guo, J; Huang, D; Xu, Q; Zhao, J	1
Chao, Y; Chi, CT; Hou, MC; Huang, YH; Hung, YP; Lee, IC; Lee, PC; Su, CW; Wu, CJ	1
Fey, D; Malik, IA; Rajput, M; Salehzadeh, N; von Arnim, CAF; Werner, R; Wilting, J	1
Hayashi, Y; Kashii, Y; Kawai, K; Minemura, M; Motofuji, Y; Muraishi, N; Murayama, A; Shimizu, Y; Shinno, E; Tajiri, K; Takahara, T; Tokimitsu, Y; Yasuda, I	1
Bi, X; Cao, C; Jiang, W; Shang, B; Shi, H; Shou, J; Wu, J; Xie, R; Zhou, A	1
Hu, L; Lin, J; Shi, X; Wang, A; Zheng, Y	1
Ahn, SH; Goh, MJ; Kang, W; Kim, BK; Kim, DY; Kim, SU; Kim, Y; Lee, HW; Lee, JS; Park, JY	1
Chen, B; Cheng, J; Lei, J; Li, Y; Lu, Y; Safadi, R; Si, T; Wu, T; Yang, X; Zhang, L; Zhang, R	1
Deng, J; Gao, J; Liao, Z	1
Bianco, V; Caponnetto, S; Cortesi, E; Marrocco, GA; Mondera, F; Pappalardo, L; Sciortino, C; Silletta, M; Tonini, G; Viglialoro, V	1
Ahn, HR; Baek, GO; Cheong, JY; Cho, HJ; Eun, JW; Kang, TW; Kim, S; Kim, SS; Kim, YB; Lim, SB; Park, W; Son, JA; Weon, JH; Yoon, JH; Yoon, MG	1
Chen, LW; Chien, RN; Chu, YD; Lin, CL; Yeh, CT	1
An, C; Fu, Y; Li, W; Wu, P; Zuo, M	1
Li, S; Liu, Q; Peng, Y; Qin, S; Tan, C; Wan, X; Wang, L; Zeng, X	1
Arabloo, J; Mohammadnezhad, G; Noqani, H; Rostamian, P; Sattarpour, M	1
Cho, Y; Hur, MH; Hyun, D; Kim, DY; Kim, GM; Kim, HC; Kim, YJ; Lee, HA; Lee, IJ; Lee, JS; Park, JW; Seo, YS; Sinn, DH	1
Amadeo, E; Aoki, T; Arai, T; Atsukawa, M; Burgio, V; Cabibbo, G; Campani, C; Casadei-Gardini, A; Cascinu, S; Cheon, J; Chon, HJ; Di Costanzo, G; Finkelmeier, F; Foschi, FG; Fukunishi, S; Hatanaka, T; Hiasa, Y; Himmelsbach, V; Hiraoka, A; Hirooka, M; Iavarone, M; Iijima, H; Imai, M; Ishikawa, T; Itobayashi, E; Itokawa, N; Iwamoto, H; Kaibori, M; Kakizaki, S; Kariyama, K; Kawata, K; Koizumi, Y; Kosaka, H; Kudo, M; Kumada, T; Lim, HY; Lonardi, S; Marra, F; Masi, G; Montes, M; Morishita, A; Nagano, T; Naganuma, A; Nakamura, S; Niizeki, T; Nishida, N; Nishimura, T; Nouso, K; Ochi, H; Ogawa, C; Ohama, H; Okubo, T; Persano, M; Presa, J; Rimini, M; Rossari, F; Sakamoto, N; Scartozzi, M; Shimada, N; Shimose, S; Sho, T; Silletta, M; Soldà, C; Stefanini, B; Steup, C; Suda, G; Tada, F; Tada, T; Tajiri, K; Takaguchi, K; Tamburini, E; Tani, J; Tovoli, F; Toyoda, H; Tsuji, K; Tsutsui, A; Vivaldi, C; Yasuda, S; Yoo, C	1
Beier, D; Ben Khaled, N; Berger-Thürmel, K; De Toni, EN; Ehmer, U; Geier, A; Kubisch, I; Lange, CM; Mayerle, J; Mörtl, B; Munker, S; Pawlowska-Phelan, D; Philipp, A; Reiter, FP; Rössler, D; Schwade, DF; Teufel, A	1
Chen, WY; Chou, TC; Lee, YY; Lin, SF; Lu, YL; Wong, RJ; Wu, MH; Yeh, CN	1
Chen, W; Gong, H; Hua, X; Liang, J; Yin, Z	1

Reviews

58 review(s) available for sorafenib and lenvatinib

Article	Year
Novel molecular targeted therapies for refractory thyroid cancer. Head & neck, 2012, Volume: 34, Issue:5 Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat	2012
Development of molecular targeted drugs for advanced thyroid cancer in Japan. Endocrine journal, 2014, Volume: 61, Issue:9 Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Japan; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms	2014
The evolving field of kinase inhibitors in thyroid cancer. Critical reviews in oncology/hematology, 2015, Volume: 93, Issue:1 Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms	2015
New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond. Anti-cancer drugs, 2015, Volume: 26, Issue:7 Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Iodine Radioisotopes; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Signal Transduction; Sorafenib; Thyroid Neoplasms; Treatment Failure	2015
Targeted therapies in advanced differentiated thyroid cancer. Cancer treatment reviews, 2015, Volume: 41, Issue:8 Topics: Antineoplastic Agents; Humans; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Quinolines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Thyroid Neoplasms	2015
Treatment of advanced thyroid cancer: role of molecularly targeted therapies. Targeted oncology, 2015, Volume: 10, Issue:3 Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A	2015
Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature. Journal of cancer research and therapeutics, 2015, Volume: 11 Suppl 2 Topics: Antineoplastic Agents; Female; Humans; Male; Neoplasm Recurrence, Local; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Publication Bias; Quinolines; Sorafenib; Thyroid Neoplasms; Treatment Outcome	2015
Targeted treatments of radio-iodine refractory differentiated thyroid cancer. Annales d'endocrinologie, 2015, Volume: 76, Issue:1 Suppl 1 Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Iodine Radioisotopes; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Randomized Controlled Trials as Topic; Sorafenib; Thyroid Neoplasms; Treatment Failure	2015
Antiangiogenic therapy in oncology: current status and future directions. Lancet (London, England), 2016, Jul-30, Volume: 388, Issue:10043 Topics: Angiogenesis Inhibitors; Angiopoietin-1; Biomarkers, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, TIE-2; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A	2016
[New molecular target therapy for thyroid neoplasms and malignant melanomas]. Nihon Jibiinkoka Gakkai kaiho, 2015, Volume: 118, Issue:11 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Ipilimumab; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Quinolines; Skin Neoplasms; Sorafenib; Sulfonamides; Thyroid Neoplasms; Vemurafenib	2015
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer treatment reviews, 2016, Volume: 50 Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA-Binding Proteins; Everolimus; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; MicroRNAs; Molecular Targeted Therapy; Mutation; Niacinamide; Nivolumab; Nuclear Proteins; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Pyrimidines; Pyrroles; Quinolines; Receptors, CCR4; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcription Factors; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein	2016
Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib. Expert review of anticancer therapy, 2016, Volume: 16, Issue:12 Topics: Antineoplastic Agents; Humans; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate; Thyroid Neoplasms; Treatment Outcome	2016
Neoadjuvant Therapy in Differentiated Thyroid Cancer. International journal of surgical oncology, 2016, Volume: 2016 Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Humans; Indazoles; Japan; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Slovenia; Sorafenib; Sulfonamides; Thyroid Neoplasms; Treatment Outcome	2016
Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2017, Volume: 37 Topics: Carcinoma, Renal Cell; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neoplasm Metastasis; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinolines; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein	2017
Second-line systemic therapy in metastatic renal-cell carcinoma: A review. Urologic oncology, 2017, Volume: 35, Issue:11 Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib	2017
Which patient with thyroid cancer deserves systemic therapy and when? Best practice & research. Clinical endocrinology & metabolism, 2017, Volume: 31, Issue:3 Topics: Antineoplastic Agents; Humans; Iodine Radioisotopes; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Analysis; Thyroid Neoplasms; Treatment Failure	2017
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life. Best practice & research. Clinical endocrinology & metabolism, 2017, Volume: 31, Issue:3 Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Humans; Iodine Radioisotopes; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Neoplasms; Treatment Failure	2017
Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer. Expert review of anticancer therapy, 2017, Volume: 17, Issue:12 Topics: Adult; Antineoplastic Agents; Disease Progression; Female; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Neoplasms; Tomography, X-Ray Computed	2017
Review article: systemic treatment of hepatocellular carcinoma. Alimentary pharmacology & therapeutics, 2018, Volume: 48, Issue:6 Topics: Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Nivolumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib	2018
Molecular therapies and precision medicine for hepatocellular carcinoma. Nature reviews. Clinical oncology, 2018, Volume: 15, Issue:10 Topics: Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Pyridines; Quinolines; Ramucirumab; Sorafenib	2018
Lenvatinib as a therapy for unresectable hepatocellular carcinoma. Expert review of anticancer therapy, 2018, Volume: 18, Issue:11 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate	2018
Optimal management of patients with hepatocellular carcinoma treated with lenvatinib. Expert opinion on drug safety, 2018, Volume: 17, Issue:11 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate	2018
Lenvatinib: A Review in Hepatocellular Carcinoma. Drugs, 2019, Volume: 79, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Treatment Outcome; Tyrosine	2019
Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. Clinical pharmacokinetics, 2019, Volume: 58, Issue:8 Topics: Aged; Aged, 80 and over; Anilides; Animals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; Liver Neoplasms; Male; Models, Animal; Molecular Targeted Therapy; Pharmacokinetics; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib; Treatment Outcome	2019
The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF Bulletin du cancer, 2019, Volume: 106, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Immunotherapy; Iodine Radioisotopes; Middle Aged; Network Meta-Analysis; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Radiation Tolerance; Sorafenib; Thyroid Neoplasms	2019
Hepatocellular carcinoma: Current situation and challenge. Hepatobiliary & pancreatic diseases international : HBPD INT, 2019, Volume: 18, Issue:4 Topics: Anilides; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Female; Humans; Liver Neoplasms; Male; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Quinolines; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome	2019
Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The lancet. Gastroenterology & hepatology, 2019, Volume: 4, Issue:9 Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Endovascular Procedures; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Liver Transplantation; Nivolumab; Patient Care Team; Phenylurea Compounds; Portal Vein; Pyridines; Quinolines; Radiotherapy, Adjuvant; Ramucirumab; Sorafenib; Stents; Venous Thrombosis	2019
Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment. International journal of molecular sciences, 2019, Sep-23, Volume: 20, Issue:19 Topics: Axitinib; Carcinoma, Renal Cell; Humans; Hypertension; Kidney Neoplasms; Phenylurea Compounds; Quinolines; Sorafenib; Sunitinib	2019
Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Medicina (Kaunas, Lithuania), 2019, Oct-17, Volume: 55, Issue:10 Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib	2019
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib. Medicina (Kaunas, Lithuania), 2019, Oct-21, Volume: 55, Issue:10 Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Quinolines; Sorafenib	2019
Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. Journal of experimental & clinical cancer research : CR, 2019, Nov-04, Volume: 38, Issue:1 Topics: Anilides; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Pyridines; Quinolines; Ramucirumab; Sorafenib; Treatment Outcome	2019
Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Alimentary pharmacology & therapeutics, 2020, Volume: 51, Issue:1 Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Humans; Immunotherapy; Liver Neoplasms; Neoplasm Staging; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib; Therapies, Investigational	2020
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC cancer, 2019, Dec-12, Volume: 19, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Humans; Iodine Radioisotopes; Meta-Analysis as Topic; Neoplasm Metastasis; Neoplasm Staging; Phenylurea Compounds; Quinolines; Randomized Controlled Trials as Topic; Sorafenib; Thyroid Neoplasms; Treatment Outcome	2019
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2020, Volume: 24, Issue:2 Topics: Antineoplastic Agents; Cost-Benefit Analysis; Humans; Iodine Radioisotopes; Phenylurea Compounds; Quality-Adjusted Life Years; Quinolines; Sorafenib; Technology Assessment, Biomedical; Thyroid Neoplasms; United Kingdom	2020
Molecular therapies for HCC: Looking outside the box. Journal of hepatology, 2020, Volume: 72, Issue:2 Topics: Algorithms; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Nivolumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib; Treatment Outcome	2020
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer treatment reviews, 2020, Volume: 84 Topics: Angiogenesis Inhibitors; Anilides; Axitinib; Carcinoma, Renal Cell; Drug Interactions; Humans; Indazoles; Kidney Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib	2020
Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis. Endocrine journal, 2020, Dec-28, Volume: 67, Issue:12 Topics: Antineoplastic Agents; Humans; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms; Treatment Outcome	2020
Targeted Molecular Therapeutic Options for Hepatocellular Carcinoma. Critical reviews in oncogenesis, 2020, Volume: 25, Issue:1 Topics: Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Phenylurea Compounds; Quinolines; Signal Transduction; Sorafenib	2020
Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review. Journal of the National Cancer Institute, 2021, 02-01, Volume: 113, Issue:2 Topics: Anilides; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib; Survival Analysis; Vascular Endothelial Growth Factor A	2021
Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. Clinics in liver disease, 2020, Volume: 24, Issue:4 Topics: Anilides; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Targeted Therapy; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinolines; Sorafenib	2020
Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges. Nutrients, 2020, Oct-12, Volume: 12, Issue:10 Topics: Cachexia; Humans; Molecular Targeted Therapy; Multicenter Studies as Topic; Muscle, Skeletal; Neoplasms; Nutrition Assessment; Nutritional Status; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Randomized Controlled Trials as Topic; Recommended Dietary Allowances; Sorafenib; Sunitinib; Treatment Outcome	2020
Multikinase inhibitors for the treatment of radioiodine refractory thyroid cancer: what have we learned from the 'real-world' experience? Current opinion in oncology, 2021, Volume: 33, Issue:1 Topics: Iodine Radioisotopes; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Radiation Tolerance; Randomized Controlled Trials as Topic; Sorafenib; Thyroid Neoplasms	2021
Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis. Internal and emergency medicine, 2021, Volume: 16, Issue:5 Topics: Gefitinib; Humans; Imatinib Mesylate; Indazoles; Muscle, Skeletal; Neoplasms; Phenylurea Compounds; Prognosis; Pyrazoles; Pyridines; Pyrimidines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis	2021
Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease. Current oncology (Toronto, Ont.), 2020, Volume: 27, Issue:Suppl 3 Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Quinolines; Sorafenib	2020
Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2021, Volume: 53, Issue:3 Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Humans; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinolines; Sorafenib; Thyroid Neoplasms	2021
Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma. Expert review of clinical pharmacology, 2021, Volume: 14, Issue:11 Topics: Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Phenylurea Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate	2021
AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma. Gastroenterology, 2022, Volume: 162, Issue:3 Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Phenylurea Compounds; Pyridines; Quinolines; Ramucirumab; Retreatment; Sorafenib	2022
Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials. Hepatology communications, 2022, Volume: 6, Issue:10 Topics: Antineoplastic Agents; Bevacizumab; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Network Meta-Analysis; Phenylurea Compounds; Quinolines; Randomized Controlled Trials as Topic; Sorafenib	2022
Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials. European journal of cancer (Oxford, England : 1990), 2022, Volume: 174 Topics: Antineoplastic Agents; Bevacizumab; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Nivolumab; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Systematic Reviews as Topic; Vascular Endothelial Growth Factor A	2022
Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios. Cancer medicine, 2022, Volume: 11 Suppl 1 Topics: Antineoplastic Agents; Humans; Iodine Radioisotopes; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Neoplasms	2022
Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer. Cancer medicine, 2022, Volume: 11 Suppl 1 Topics: Adenocarcinoma; Antineoplastic Agents; Humans; Iodine Radioisotopes; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Neoplasms	2022
Resistance of Lenvatinib in Hepatocellular Carcinoma. Current cancer drug targets, 2022, Volume: 22, Issue:11 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Quinolines; Sorafenib	2022
Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study. Anticancer research, 2022, Volume: 42, Issue:12 Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Retrospective Studies; Sorafenib	2022
Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: A systematic review and network meta-analysis of safety. Cancer medicine, 2023, Volume: 12, Issue:6 Topics: Antineoplastic Agents; Bayes Theorem; Carcinoma, Renal Cell; Everolimus; Humans; Kidney Neoplasms; Network Meta-Analysis; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A	2023
Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis. Clinics and research in hepatology and gastroenterology, 2023, Volume: 47, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib	2023
Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis. Current oncology (Toronto, Ont.), 2023, 01-16, Volume: 30, Issue:1 Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Portal Vein; Sorafenib; Thrombosis; Treatment Outcome; Tyrosine Kinase Inhibitors	2023
Lenvatinib in the treatment of unresectable hepatocellular carcinoma: a systematic review of economic evaluations. European journal of clinical pharmacology, 2023, Volume: 79, Issue:7 Topics: Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A	2023
Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study. European journal of gastroenterology & hepatology, 2024, Jan-01, Volume: 36, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib	2024

Trials

11 trial(s) available for sorafenib and lenvatinib

Article	Year
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinolines; Quinolones; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome; Valproic Acid	2013
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet (London, England), 2018, 03-24, Volume: 391, Issue:10126 Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Quinolines; Sorafenib; Survival Rate; Treatment Outcome	2018
Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial. BMC cancer, 2019, Jun-14, Volume: 19, Issue:1 Topics: Antineoplastic Agents; Benzimidazoles; Clinical Trials, Phase II as Topic; Humans; Iodine Radioisotopes; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Metastasis; Phenylurea Compounds; Quinolines; Sorafenib; Thyroid Neoplasms; United Kingdom	2019
Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. British journal of cancer, 2019, Volume: 121, Issue:3 Topics: Carcinoma, Hepatocellular; Creatinine; Humans; Liver Neoplasms; Phenylurea Compounds; Proteinuria; Quinolines; Sorafenib	2019
REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. Journal of gastroenterology, 2020, Volume: 55, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Intention to Treat Analysis; Japan; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Quinolines; Sorafenib; Survival Analysis; Treatment Outcome	2020
Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. British journal of cancer, 2020, Volume: 122, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Phenylurea Compounds; Prognosis; Quinolines; Risk Factors; Sorafenib	2020
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. The lancet. Gastroenterology & hepatology, 2021, Volume: 6, Issue:8 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Staging; Patient Reported Outcome Measures; Phenylurea Compounds; Quinolines; Sorafenib; Treatment Outcome	2021
Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study. Cancer, 2021, 10-15, Volume: 127, Issue:20 Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Phenylurea Compounds; Portal Vein; Prospective Studies; Quinolines; Retrospective Studies; Sorafenib; Thrombosis; Treatment Outcome	2021
Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis. BMC gastroenterology, 2022, Mar-25, Volume: 22, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Humans; Liver Neoplasms; Phenylurea Compounds; Propensity Score; Quinolines; Retrospective Studies; Sorafenib; Treatment Outcome	2022
Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI). Thyroid : official journal of the American Thyroid Association, 2022, Volume: 32, Issue:9 Topics: Adenocarcinoma; Antineoplastic Agents; Cohort Studies; Humans; Iodine Radioisotopes; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Neoplasms	2022
Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis. Clinics and research in hepatology and gastroenterology, 2023, Volume: 47, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib	2023

Other Studies

83 other study(ies) available for sorafenib and lenvatinib

Article	Year
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. European journal of medicinal chemistry, 2010, Volume: 45, Issue:11 Topics: Drug Evaluation, Preclinical; Models, Molecular; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor Receptor-2	2010
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15 Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship	2013
Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS medicinal chemistry letters, 2015, Jan-08, Volume: 6, Issue:1 Topics:	2015
Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer. Journal of medicinal chemistry, 2015, May-14, Volume: 58, Issue:9 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Kinesins; Lung Neoplasms; Models, Molecular; Protein Conformation	2015
Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines. Journal of medicinal chemistry, 2018, 01-11, Volume: 61, Issue:1 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Protein Conformation; Protein Kinase Inhibitors; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2	2018
The target landscape of clinical kinase drugs. Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays	2017
[Molecular targeting treatment for thyroid cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:7 Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Quinolines; Sorafenib; Thyroid Neoplasms	2015
Efficacy of lenvatinib in treating thyroid cancer. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:12 Topics: Biomarkers; Calcitonin; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Half-Life; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroglobulin; Thyroid Neoplasms	2016
[Lenvatinib in radioiodine refractory thyroid carcinomas]. Bulletin du cancer, 2016, Volume: 103, Issue:11 Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Clinical Trials as Topic; Compassionate Use Trials; Humans; Iodine Radioisotopes; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Neoplasms	2016
Timing of multikinase inhibitor initiation in differentiated thyroid cancer. Endocrine-related cancer, 2017, Volume: 24, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Drug Administration Schedule; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Salvage Therapy; Sorafenib; Thyroid Neoplasms; Time Factors; Treatment Failure	2017
Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer. Thyroid : official journal of the American Thyroid Association, 2017, Volume: 27, Issue:8 Topics: Aged; Antineoplastic Agents; Cell Differentiation; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Drug Costs; Female; Health Care Costs; Humans; Male; Middle Aged; Models, Economic; Monte Carlo Method; Neoplasm Grading; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quality of Life; Quinolines; Sorafenib; Survival Analysis; Thyroid Neoplasms; Tumor Burden; United States	2017
Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice. Endocrine, 2018, Volume: 59, Issue:2 Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate; Thyroid Neoplasms; Treatment Outcome	2018
Liver cancer: Lenvatinib non-inferior to sorafenib for hepatocellular carcinoma. Nature reviews. Gastroenterology & hepatology, 2018, Volume: 15, Issue:4 Topics: Adult; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Quinolines; Sorafenib	2018
Number needed to treat in indirect treatment comparison. Journal of comparative effectiveness research, 2018, Volume: 7, Issue:3 Topics: Antineoplastic Agents; Humans; Iodine Radioisotopes; Numbers Needed To Treat; Phenylurea Compounds; Quinolines; Sorafenib; Statistics as Topic; Thyroid Neoplasms	2018
Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria. Auris, nasus, larynx, 2018, Volume: 45, Issue:6 Topics: Aged; Antineoplastic Agents; Drug Substitution; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Phenylurea Compounds; Proteinuria; Quinolines; Radiation Tolerance; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome	2018
Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families. Biochemical and biophysical research communications, 2018, 10-12, Volume: 504, Issue:4 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Matrix Metalloproteinases; Molecular Targeted Therapy; Multigene Family; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib; Tissue Inhibitor of Metalloproteinases	2018
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer science, 2018, Volume: 109, Issue:12 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Cell Survival; Immunocompetence; Immunomodulation; Liver Neoplasms; Mice; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Quinolines; Sequence Analysis, RNA; Single-Cell Analysis; Sorafenib; Xenograft Model Antitumor Assays	2018
Perforating dermatosis associated with multikinase inhibitors: report of two cases, including one associated with lenvatinib. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2018, Volume: 16, Issue:12 Topics: Abdomen; Aged; Carcinoma; Carcinoma, Hepatocellular; Folliculitis; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Skin Diseases; Sorafenib; Thigh; Thyroid Neoplasms	2018
Rare complications of multikinase inhibitor treatment. Archives of endocrinology and metabolism, 2018, Volume: 62, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Medullary; Female; Follow-Up Studies; Heart Failure; Humans; Intestinal Perforation; Kaplan-Meier Estimate; Male; Middle Aged; Oophoritis; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Retrospective Studies; Risk Factors; Sorafenib; Thrombocytopenia; Thyroid Neoplasms; Time Factors; Young Adult	2018
Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation. Chemical biology & drug design, 2019, Volume: 93, Issue:5 Topics: Binding Sites; Humans; Hydrogen Bonding; Molecular Dynamics Simulation; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinolines; Sorafenib; Static Electricity; Sunitinib; Thermodynamics; Vascular Endothelial Growth Factor Receptor-2	2019
Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. Journal of gastroenterology, 2019, Volume: 54, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Japan; Liver Neoplasms; Models, Economic; Phenylurea Compounds; Quality-Adjusted Life Years; Quinolines; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis	2019
The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer. Endocrine, 2019, Volume: 64, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Retrospective Studies; Sorafenib; Thyroid Neoplasms	2019
Real-World Treatment Patterns Among Patients Initiating Small Molecule Kinase Inhibitor Therapies for Thyroid Cancer in the United States. Advances in therapy, 2019, Volume: 36, Issue:4 Topics: Databases, Factual; Drug Utilization Review; Female; Humans; Male; Middle Aged; Molecular Targeted Therapy; Phenylurea Compounds; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Quinolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Neoplasms; United States	2019
US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology: A Dangerous Precedent? JAMA oncology, 2019, May-01, Volume: 5, Issue:5 Topics: Antineoplastic Agents; Drug Approval; Equivalence Trials as Topic; Humans; Neoplasms; Phenylurea Compounds; Quinolines; Sorafenib; United States; United States Food and Drug Administration	2019
Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice. Molecular cancer therapeutics, 2019, Volume: 18, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Heterografts; Humans; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Carcinoma, Anaplastic	2019
Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis. World journal of gastroenterology, 2019, Jul-21, Volume: 25, Issue:27 Topics: Aged; Argentina; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Neoplasm Staging; Phenylurea Compounds; Prospective Studies; Quinolines; Retrospective Studies; Sorafenib; Treatment Outcome	2019
Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study. Thyroid : official journal of the American Thyroid Association, 2019, Volume: 29, Issue:12 Topics: Aged; Antineoplastic Agents; Cohort Studies; Female; Humans; Iodine Radioisotopes; Kaplan-Meier Estimate; Male; Middle Aged; Phenylurea Compounds; Progression-Free Survival; Quinolines; Republic of Korea; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Analysis; Thyroid Neoplasms; Treatment Outcome	2019
Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. Nature communications, 2019, 10-15, Volume: 10, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Gene Knock-In Techniques; Gene Knockout Techniques; Humans; Liver Neoplasms; Phenylurea Compounds; Phosphoglycerate Dehydrogenase; Pyridines; Quinolines; Reactive Oxygen Species; Sorafenib	2019
Renal dysfunction in patients with radioactive iodine-refractory thyroid cancer treated with tyrosine kinase inhibitors: A retrospective study. Medicine, 2019, Volume: 98, Issue:42 Topics: Aged; Drug Substitution; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Iodine Radioisotopes; Kidney Diseases; Male; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinolines; Radiation Tolerance; Retrospective Studies; Sorafenib; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome	2019
A report of a new late toxic effect of lenvatinib. Chinese medical journal, 2020, Mar-20, Issue:6 Topics: Carcinoma, Hepatocellular; Humans; Phenylurea Compounds; Quinolines; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2	2020
Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis. The oncologist, 2020, Volume: 25, Issue:3 Topics: Antineoplastic Agents; Canada; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Phenylurea Compounds; Quinolines; Sorafenib	2020
Sorafenib Anticancer research, 2020, Volume: 40, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Portal Vein; Quinolines; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome; Venous Thrombosis	2020
Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells. Cell death & disease, 2020, 05-07, Volume: 11, Issue:5 Topics: Adult; Anilides; Apoptosis; Cell Culture Techniques; Cell Differentiation; Cell Proliferation; Cell Respiration; Female; Hep G2 Cells; Hepatocytes; Humans; Liver Neoplasms; Male; Mitochondria; Oxygen Consumption; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib; Spheroids, Cellular; Tumor Suppressor Protein p53	2020
Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines. International journal of molecular sciences, 2020, May-09, Volume: 21, Issue:9 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Hep G2 Cells; Humans; Immunity, Innate; Liver Neoplasms; Neoplasm Proteins; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyridines; Quinolines; Real-Time Polymerase Chain Reaction; Signal Transduction; Sorafenib; Toll-Like Receptors; Transcriptome	2020
Sequential systemic treatment in patients with hepatocellular carcinoma. Alimentary pharmacology & therapeutics, 2020, Volume: 52, Issue:1 Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Nivolumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib	2020
Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling. Carcinogenesis, 2021, 02-11, Volume: 42, Issue:1 Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Fibroblast Growth Factor 2; Fibroblast Growth Factors; Fluorouracil; Humans; Liver Neoplasms; Mice; Molecular Targeted Therapy; Neoplastic Stem Cells; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Receptor, Fibroblast Growth Factor, Type 4; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays	2021
Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors. Oncology, 2020, Volume: 98, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Retrospective Studies; Sorafenib; Young Adult	2020
Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib. Oncology, 2020, Volume: 98, Issue:11 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Ramucirumab; Retrospective Studies; Sorafenib; Survival Rate	2020
Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia. Clinical drug investigation, 2020, Volume: 40, Issue:12 Topics: Antineoplastic Agents; Australia; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Female; Humans; Liver Neoplasms; Male; Phenylurea Compounds; Quality-Adjusted Life Years; Quinolines; Sorafenib	2020
Combining immune checkpoint inhibitor with lenvatinib prolongs survival than lenvatinib alone in sorafenib-experienced hepatocellular carcinoma patients. European journal of gastroenterology & hepatology, 2022, 02-01, Volume: 34, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Male; Phenylurea Compounds; Quinolines; Sorafenib; Survival Analysis	2022
ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. Journal of hepatology, 2021, Volume: 74, Issue:4 Topics: ADAMTS Proteins; ADAMTS5 Protein; Animals; Antineoplastic Agents, Immunological; Benzocycloheptenes; Carcinogenesis; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Epigenomics; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Phenylurea Compounds; Quinolines; Signal Transduction; Sorafenib; Transcriptional Activation; Triazoles; Tumor Microenvironment	2021
Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma. Journal of gastroenterology and hepatology, 2021, Volume: 36, Issue:5 Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Quinolines; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome	2021
ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 02-15, Volume: 27, Issue:4 Topics: Aged; Aged, 80 and over; Animals; Antigens, CD; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease-Free Survival; Down-Regulation; Drug Resistance, Neoplasm; Female; Fibroblast Growth Factors; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Middle Aged; Neoplasm Recurrence, Local; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sialyltransferases; Sorafenib	2021
Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy. Cellular and molecular gastroenterology and hepatology, 2021, Volume: 11, Issue:5 Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Disease Models, Animal; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Precision Medicine; Prognosis; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thioacetamide; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays	2021
Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma. Internal medicine (Tokyo, Japan), 2021, Volume: 60, Issue:3 Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Phenylurea Compounds; Prospective Studies; Quinolines; Sorafenib	2021
Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Probability; Quinolines; Sorafenib	2021
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. Scientific reports, 2021, 03-05, Volume: 11, Issue:1 Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Fibroblast Growth Factors; Humans; Liver Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Receptor, Fibroblast Growth Factor, Type 4; Sorafenib	2021
Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy. Oncology, 2021, Volume: 99, Issue:5 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Prognosis; Pyridines; Quinolines; Ramucirumab; Retrospective Studies; Sorafenib; Survival Rate	2021
Sorafenib and Lenvatinib as first-line treatment of hepatocellular carcinoma: A still controversial comparison. Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:6 Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Probability; Quinolines; Sorafenib	2021
The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors. Medical oncology (Northwood, London, England), 2021, Apr-21, Volume: 38, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Blood Vessels; Carcinoma, Hepatocellular; Female; Liver Neoplasms, Experimental; Mice, Inbred BALB C; Phenylurea Compounds; Quinolines; Sorafenib; Tumor Hypoxia; X-Ray Microtomography	2021
Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. Journal of gastroenterology, 2021, Volume: 56, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Body Weight; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Quinolines; Sorafenib; Treatment Outcome	2021
Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma. Oncology, 2021, Volume: 99, Issue:8 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome	2021
Quantification of sorafenib, lenvatinib, and apatinib in human plasma for therapeutic drug monitoring by UPLC-MS/MS. Journal of pharmaceutical and biomedical analysis, 2021, Aug-05, Volume: 202 Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Drug Monitoring; Humans; Liver Neoplasms; Pharmaceutical Preparations; Phenylurea Compounds; Pyridines; Quinolines; Reproducibility of Results; Sorafenib; Tandem Mass Spectrometry	2021
Acetylation-induced PCK isoenzyme transition promotes metabolic adaption of liver cancer to systemic therapy. Cancer letters, 2021, 10-28, Volume: 519 Topics: Acetylation; Adaptation, Physiological; Cell Line; Cell Line, Tumor; Cytoplasm; HEK293 Cells; Hep G2 Cells; Histone Acetyltransferases; Humans; Isoenzymes; Liver; Liver Neoplasms; Neoplasm Recurrence, Local; Phenylurea Compounds; Phosphoenolpyruvate Carboxykinase (ATP); Progression-Free Survival; Quinolines; Sorafenib	2021
Transient deterioration of albumin-bilirubin scores in early post-dose period of molecular targeted therapies in advanced hepatocellular carcinoma with 50% or higher liver occupation: A STROBE-compliant retrospective observational study. Medicine, 2021, Aug-06, Volume: 100, Issue:31 Topics: Aged; Antineoplastic Agents; Bilirubin; Biomarkers, Pharmacological; C-Reactive Protein; Carcinoma, Hepatocellular; Correlation of Data; Drug Monitoring; Drug Screening Assays, Antitumor; Female; Humans; Japan; Liver; Liver Neoplasms; Male; Molecular Targeted Therapy; Neoplasm Staging; Phenylurea Compounds; Quinolines; Serum Albumin; Sorafenib	2021
Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival. Oncology, 2021, Volume: 99, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Phenylurea Compounds; Propensity Score; Quinolines; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome	2021
Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells. International journal of molecular sciences, 2021, Dec-02, Volume: 22, Issue:23 Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice, Inbred BALB C; MicroRNAs; Neovascularization, Pathologic; Phenylurea Compounds; Quinolines; Sorafenib; Xenograft Model Antitumor Assays	2021
Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib: A novel therapy exploiting tumor-platelet interactions. International journal of cancer, 2022, 05-15, Volume: 150, Issue:10 Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Endothelial Cells; Humans; Liver Neoplasms; Phenylurea Compounds; Quinolines; Rats; Sorafenib	2022
Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation. Digestive diseases and sciences, 2022, Volume: 67, Issue:10 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Quinolines; Retrospective Studies; Sorafenib	2022
Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer. International journal of molecular sciences, 2022, Jan-09, Volume: 23, Issue:2 Topics: Adult; Aged; Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Middle Aged; Paclitaxel; Phenylurea Compounds; Prognosis; Quinolines; RNA-Seq; Sorafenib; Thyroid Cancer, Papillary; Xenograft Model Antitumor Assays	2022
AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma. Gastroenterology, 2022, Volume: 162, Issue:3 Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Phenylurea Compounds; Pyridines; Quinolines; Ramucirumab; Retreatment; Sorafenib	2022
Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy. Cancer reports (Hoboken, N.J.), 2022, Volume: 5, Issue:11 Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Geriatric Assessment; Humans; Liver Neoplasms; Sorafenib	2022
Differences Between Sorafenib and Lenvatinib Treatment from Genetic and Clinical Perspectives for Patients with Hepatocellular Carcinoma. Medical science monitor : international medical journal of experimental and clinical research, 2022, Apr-27, Volume: 28 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; MicroRNAs; Phenylurea Compounds; Quinolines; Sorafenib	2022
Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma. Medicine, 2022, May-13, Volume: 101, Issue:19 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Kidney; Liver Neoplasms; Phenylurea Compounds; Proteinuria; Quinolines; Sorafenib	2022
Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer. Cellular oncology (Dordrecht), 2022, Volume: 45, Issue:5 Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Organoids; Ribosomal Protein S6 Kinases; Sorafenib; TOR Serine-Threonine Kinases	2022
Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats. Molecules (Basel, Switzerland), 2022, Aug-24, Volume: 27, Issue:17 Topics: Animals; Canagliflozin; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Drug Interactions; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Rats; Sodium-Glucose Transporter 2 Inhibitors; Sorafenib	2022
LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma. Experimental cell research, 2022, 11-01, Volume: 420, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; E2F2 Transcription Factor; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Octamer Transcription Factor-1; Phenylurea Compounds; Quinolines; RNA, Long Noncoding; Sorafenib; Transcription Factors	2022
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO open, 2022, Volume: 7, Issue:6 Topics: Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Propensity Score; Retrospective Studies; Sorafenib	2022
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study. Medicine, 2022, Oct-07, Volume: 101, Issue:40 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Targeted Therapy; Phenylurea Compounds; Quinolines; Sorafenib	2022
Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial-Mesenchymal Transition and Metastasis. International journal of radiation oncology, biology, physics, 2023, 03-01, Volume: 115, Issue:3 Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Liver Neoplasms; Negotiating; NF-kappa B; Sorafenib; STAT3 Transcription Factor	2023
Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment. Viruses, 2022, 10-26, Volume: 14, Issue:11 Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Humans; Liver Neoplasms; Retrospective Studies; Sorafenib	2022
Differential in vitro effects of targeted therapeutics in primary human liver cancer: importance for combined liver cancer. BMC cancer, 2022, Nov-19, Volume: 22, Issue:1 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholangiocarcinoma; Dasatinib; Hepatoblastoma; Humans; Liver Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Sirolimus; Sorafenib	2022
Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma. European journal of gastroenterology & hepatology, 2023, 02-01, Volume: 35, Issue:2 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Middle Aged; Nivolumab; Phenylurea Compounds; Sorafenib; Treatment Failure	2023
Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study. Drug design, development and therapy, 2022, Volume: 16 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Neoplasms; Phenylurea Compounds; Quinolines; Retrospective Studies; Risk Factors; Sorafenib	2022
Lenvatinib Anticancer research, 2023, Volume: 43, Issue:2 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatocytes; Humans; Liver Neoplasms; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome	2023
Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib. Cancer communications (London, England), 2023, Volume: 43, Issue:4 Topics: Cancer-Associated Fibroblasts; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Osteopontin; Phosphatidylinositol 3-Kinases; Sorafenib	2023
Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib. Cancer biomarkers : section A of Disease markers, 2023, Volume: 36, Issue:3 Topics: Carcinoma, Hepatocellular; Genotype; Humans; Liver Neoplasms; Prognosis; Sorafenib	2023
Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy. Cancer, 2023, 07-15, Volume: 129, Issue:14 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Infusions, Intra-Arterial; Liver Neoplasms; Sorafenib; Treatment Outcome	2023
First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. PloS one, 2023, Volume: 18, Issue:4 Topics: Bevacizumab; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Quality-Adjusted Life Years; Sorafenib; Sunitinib	2023
Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis. Clinical and molecular hepatology, 2023, Volume: 29, Issue:3 Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Portal Vein; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Thrombosis; Treatment Outcome; Tyrosine Kinase Inhibitors	2023
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients. European journal of cancer (Oxford, England : 1990), 2023, Volume: 189 Topics: Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Retrospective Studies; Sorafenib	2023
Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study. European journal of cancer (Oxford, England : 1990), 2023, Volume: 192 Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Sorafenib	2023
Therapeutic inhibition of ATR in differentiated thyroid cancer. Endocrine-related cancer, 2023, 12-01, Volume: 30, Issue:12 Topics: Adenocarcinoma; Animals; Ataxia Telangiectasia Mutated Proteins; Humans; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms	2023